RxDoctor Payments Data

Katarzyna Calderon

Family · Philadelphia, PANPI 1053564849

Payments from drug & device makers

$1,209in general payments, 2019–2025

Across 60 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$199
  • Neurocrine Biosciences, Inc.$159
  • Otsuka America Pharmaceutical, Inc.$111
  • Teva Pharmaceuticals USA, Inc.$108
  • Novartis$107
  • UCB, Inc.$96
  • plus $428 from 9 others

What the payments were for

  • Food & beverage$1,209100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,209 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$56,423
Medicare patients
153
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$53,015
JardianceEmpagliflozin16$23,236
TrulicityDulaglutide19$13,590
JanuviaSitagliptin Phosphate19$13,225
BrilintaTicagrelor12$5,670
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$4,598
XareltoRivaroxaban13$4,521
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$4,089
Atorvastatin Calcium218$3,218
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,046
Losartan Potassium105$1,732
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide11$1,237
Levothyroxine Sodium111$1,234
Amlodipine Besylate100$972
Albuterol Sulfate HfaAlbuterol Sulfate28$971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$53,01556 claims
Lilly USA, LLCTrulicity$199$13,59019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →